

Part VI: Summary of the risk management plan

Summary of risk management plan for Emoxen/Apranax Protect (Naproxen + Esomeprazole)

This is a summary of the risk management plan (RMP) for Emoxen/Apranax Protect. The RMP details important risks of Emoxen/Apranax Protect, how these risks can be minimised, and how more information will be obtained about Emoxen/Apranax Protect risks and uncertainties (missing information).

Emoxen/Apranax Protect summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Emoxen/Apranax Protect should be used.

Important new concerns or changes to the current ones will be included in updates of Emoxen/Apranax Protect RMP.

I. The medicine and what it is used for

Emoxen/Apranax Protect is authorised for symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers (see SmPC for the full indication). It contains naproxen + esomeprazole as the active substances, and it is given by oral route of administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Emoxen/Apranax Protect, together with measures to minimise such risks and the proposed studies for learning more about Emoxen/Apranax Protect risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Emoxen/Apranax Protect are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Emoxen/Apranax Protect. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information *	
Important identified risks	None
Important potential risks	None
Missing information	None

* In accordance with the current legislation in vigour (GVP Module V Rev. 2 and HaRP), there are no safety concerns to be addressed for naproxen/esomeprazole.

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product Vimovo.

II.C Post-authorisation development plan**II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of Emoxen/Apranax Protect.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Emoxen/Apranax Protect.